Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection

摘要

It is described the use of ribavirin and interferon alpha for the manufacture a pharmaceutical compositions for treating antiviral treatment naive patient having chronic hepatitis C infection to eradicate detectable HCV-RNA involving a combination therapy using a therapeutically effective amount of ribavirin and a therapeutically effective amount of interferon alpha for a time period of from 40 up to 50 weeks.